膀胱肿瘤在我国泌尿系统肿瘤中位居第一,且有极高的复发率,因而早期诊断和监测复发就很重要。尿细胞学检查和膀胱镜是目前诊断监测膀胱癌的传统方法,但都有局限性。膀胱癌生物学标记因其简单无创和敏感性等特点被人们寄予厚望。但目前研究的一些肿瘤标记物如BTA、BTAstat、BTA-TRAK以及NMP22等由于种种原因尚不能取代传统的尿细胞学和膀胱镜。因而人们一直在努力寻找一种更理想的肿瘤标记物。本文就目前膀胱肿瘤标记物的研究进展作一综述。 Bladder cancer ranks first in our country urological system tumors, and has a very high recurrence rate, so early diagnosis and monitoring of recurrence is very important. Urinalysis and cystoscopy are the traditional methods of diagnosis and monitoring of bladder cancer, but all have limitations. Bladder cancer biomarkers are highly anticipated because of their simplicity and noninvasiveness. However, some of the currently studied tumor markers such as BTA, BTAstat, BTA-TRAK and NMP22 can not replace traditional urinary cytology and cystoscopy for a variety of reasons. So people have been trying to find a more ideal tumor marker. This article reviews the current research progress of bladder tumor markers.